Mucosal Melanoma Second Opinion After Immunotherapy Failure:
A Remote Case Study

Why This Case Matters

For families facing rare cancer progression, the key question is often not only what options remain when standard treatment is no longer effective, but whether those options can be evaluated safely, remotely, and objectively before travel decisions are made.

In this case, the patient had metastatic mucosal melanoma with progression after ipilimumab and nivolumab, while active jaundice, spinal pain, and cardiovascular history made immediate long-haul travel clinically complex. The case illustrates how a remote second opinion can help international families assess advanced melanoma treatment options overseas without first committing to medical travel.

 

Patient Profile & Clinical Background

• Demographics: An elderly male patient in his mid-80s from North America, diagnosed with metastatic anal melanoma (a mucosal melanoma subtype).

• Documentation Volume: MedBridgeNZ processed a secure transfer of clinical data, including 1 ZIP file, 3 primary PDF medical reports, completed intake forms, and secure cloud drive imaging links.

• Clinical Data: Initial clinical staging was cT3, cN1, cM0. The patient later presented with progressive distant metastases in the inguinal lymph nodes, liver, and spine, accompanied by the recent onset of severe back pain and clinical jaundice.

• Genetic & Biomarker Profile:

  • TERT promoter Pathogenic Variant (-124C>T)

  • BRAF Variant of Uncertain Significance (Exon 11 p.F468C)

  • PD-L1 Tumor Proportion Score (TPS): 0%

  • Tumor Mutational Burden (TMB): Low (4 mut/Mb)

  • Microsatellite Instability (MSI): Stable

• Treatment History & Comorbidities: A recent PET scan indicated hyper-progression despite ongoing dual immunotherapy (CTLA-4 + PD-1 / ipilimumab + nivolumab). The patient's complex medical history includes a coronary stent, hypertension, and high cholesterol, necessitating rigorous cardiovascular safety evaluations for any future regimens.

 

The Challenge & Treatment Goal

The primary clinical challenge was the rapid tumor progression and confirmed resistance to standard dual immunotherapy. The local oncology team recommended halting current immunotherapy and transitioning to palliative care or clinical trials. Furthermore, the unusual BRAF mutation variant rendered standard BRAF + MEK inhibitors clinically unviable. The recent onset of jaundice and back pain also significantly complicated the safe introduction of any new systemic therapies.

 

The patient's family engaged MedBridgeNZ with a specific goal: to bypass standard local limitations and secure an expedited, comprehensive Second Medical Opinion from a leading specialist in mucosal melanoma at Fudan University Shanghai Cancer Center. The objective was to evaluate the safety and viability of a targeted "Triplet Therapy" previously unavailable or unconsidered in their local care plan.

​

For families considering a remote specialist review before making travel decisions, MedBridgeNZ can help organize medical records, translation, and coordination with appropriate medical institutions.

 

Timeline of Care & Concierge Services

• Initial Contact: MedBridgeNZ completed the initial clinical triage and proposed two distinct facilitation pathways (Remote Assessment vs. Direct Expedited Travel).

• Day 2: The family elected the Comprehensive Remote Assessment. MedBridgeNZ received the completed consultation forms alongside the initial batch of medical records and confirmed payment processing.

• Day 4 (Friction & Resolution): MedBridgeNZ clinical coordinators identified a discrepancy in the submitted intake form: the family inadvertently listed their local North American oncologist instead of the requested Shanghai specialist. Translation protocols were paused until written clarification was secured from the family.

• Day 5: The discrepancy was resolved. The expedited medical translation process was completed, and the formalized case was submitted to the specialist. MedBridgeNZ subsequently forwarded the expert's preliminary assessment on symptom management.

• Day 6: The family submitted exactly 6 follow-up clinical and logistical questions, addressing treatment timelines, scan frequencies, specific side effects, and visa documentation. These were translated and escalated to the specialist.

• Week 2: MedBridgeNZ delivered the finalized comprehensive Remote Consultation Medical Report (Second Opinion) and provided a customized monthly out-of-pocket cost estimate for the targeted medications to assist the family with concrete financial planning.

 

Consultation Outcomes & Strategic Roadmap

 

Specialist Review and Institution Context

The remote consultation was coordinated with a senior mucosal melanoma specialist at Fudan University Shanghai Cancer Center. The institution is one of China’s major tertiary oncology centers, with clinical experience in complex and advanced melanoma cases.

 

The purpose of the review was not to replace the patient’s local oncology team, but to obtain a case-specific specialist perspective that the family could discuss with their treating physicians.

 

Case-Specific Strategic Roadmap

Based on the submitted medical records, imaging history, biomarker profile, and prior treatment response, the specialist formulated a case-specific triplet therapy roadmap for discussion with the patient’s local oncology team.

 

The proposed roadmap included:

• An oral anti-angiogenic targeted drug

• Oral temozolomide

• A PD-L1 antibody

 

This roadmap was framed as a specialist-proposed strategy for this individual case, not as a general recommendation for other patients with mucosal melanoma. Any decision to pursue, adapt, or reject the approach would remain with the patient’s treating physicians and local oncology team.

 

Symptom Management Priorities

Before any further systemic therapy could be considered, the specialist emphasized the need to address the patient’s active symptoms and immediate clinical risks.

 

Two priorities were identified for local evaluation:

• Palliative spinal radiotherapy to help manage severe back pain related to spinal involvement

• PTCD, or percutaneous transhepatic cholangiography and drainage, to help lower bilirubin levels associated with liver metastases and clinical jaundice

 

These symptom management steps were presented as prerequisite considerations because the patient’s jaundice, pain burden, and overall frailty could affect the safety and timing of any further systemic treatment.

 

Travel Feasibility & Logistical Realities

MedBridgeNZ also provided a practical assessment of the medical travel pathway. In this case, international travel was not treated as an automatic next step.

 

The Oncology Department could not issue an official Medical Invitation Letter for an S1/S2 visa pathway for this specific consultation route. This limitation was communicated clearly to the family so that travel planning would not be based on unrealistic assumptions.

 

The specialist also issued a strong clinical caution regarding long-haul travel. Given the patient’s active jaundice, severe spinal pain, metastatic disease burden, and advanced age, an international flight could place significant physical strain on the patient.

 

As a result, the remote second opinion gave the family a more realistic pathway: rather than immediately pursuing overseas travel, they could bring the specialist’s roadmap, symptom management priorities, and translated documentation back to their local oncology team for further discussion. This allowed the family to evaluate treatment feasibility and clinical risk without committing the patient to high-risk travel at that stage.

​​

What This Case Demonstrates

This case demonstrates how a remote specialist review can help families evaluate clinical options and travel feasibility before committing to international medical travel. MedBridgeNZ’s role centered on record organization, medical translation, specialist communication, and objective logistical coordination, enabling the family to discuss the specialist’s roadmap with their local oncology team.

​​

Medical Disclaimer

Disclaimer: MedBridgeNZ is a medical concierge and facilitation service, not a healthcare provider. We do not offer medical advice, diagnosis, or treatment. All clinical decisions and medical treatments are solely the responsibility of the treating physicians and medical institutions. The clinical outcomes or strategic roadmaps described in this case study are specific to this individual and do not guarantee similar results for other patients.